<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247870</url>
  </required_header>
  <id_info>
    <org_study_id>10.0086</org_study_id>
    <secondary_id>2010-020818-28</secondary_id>
    <nct_id>NCT01247870</nct_id>
  </id_info>
  <brief_title>Metformin in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Trial of Metformin in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Lung Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St George's, University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a tablet medication, called
      metformin, in flare-ups (exacerbations) of chronic obstructive pulmonary disease. The
      investigators believe that metformin may effectively control the blood sugar level during
      COPD exacerbations. This is important because there is evidence that a high blood sugar level
      during exacerbations may be linked with a worse prognosis. The investigators also think that
      metformin may have other potentially useful effects on inflammation, antioxidant levels, the
      effectiveness of steroid treatment, and recovery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Does metformin lower the blood sugar level in patients suffering from exacerbations of
      chronic obstructive pulmonary disease (COPD)?

      COPD is the fourth leading cause of death worldwide, and a major cause of ill health. In the
      UK, it affects some 3.7 million people and causes over 30,000 deaths per year. It is usually,
      but not always, caused by smoking. Most people affected are over 65-years-old. Sufferers
      experience progressively worsening cough, sputum production, breathlessness and exercise
      limitation. This is punctuated by 'flare-ups' (exacerbations), when their symptoms worsen
      substantially. Approximately 25% of patients hospitalised for exacerbations die within a
      year, and over 50% within 5 years. There is a pressing need for new and improved treatments
      for COPD exacerbations.

      This study will assess the effect of metformin, a tablet medication, in COPD exacerbations.
      Metformin has been in common use for over 50 years in patients with diabetes, to lower the
      blood sugar level. In COPD exacerbations, the blood sugar level is often high, and the higher
      it is, the more likely the patient will have a poor outcome. This led us to speculate that
      lowering the sugar level with metformin may improve outcomes from COPD exacerbations.
      However, COPD and diabetes are quite different diseases, and the investigators do not know
      whether metformin will work as a sugar-lowering medicine in COPD exacerbations. The
      investigators need to confirm this before the investigators can perform larger studies to
      assess its effect on outcomes such as readmission and mortality rates.

      The investigators will test this medicine in a 1-month trial in patients hospitalised for
      COPD exacerbations. The target sample size is 69 patients, with a minimum of 48 patients
      required for primary endpoint analysis. Two-thirds of the patients will take metformin, and
      one-third a dummy (placebo) tablet. Neither the patients nor the researchers know who is
      taking which. The investigators will measure their sugar levels by regular finger-prick
      tests, and then compare the average readings in the two groups. The investigators will also
      assess the medicine's effects on other markers of blood sugar level, and carry out additional
      exploratory investigations on the effect of the medicine on clinical outcomes, markers of
      inflammation, and markers of oxidative/carbonyl stress and steroid responsiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Capillary glucose concentration</measure>
    <time_frame>During hospitalisation period</time_frame>
    <description>The mean capillary glucose concentration during hospitalisation period following study entry, as a measure of both efficacy and safety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment Test score</measure>
    <time_frame>Study entry, hospital discharge, and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation of Chronic Pulmonary Disease Tool (EXACT) score</measure>
    <time_frame>Days 5, 10 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>Hospital discharge</time_frame>
    <description>Number of days from hospital admission to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent exacerbation, readmission, and death rate</measure>
    <time_frame>3 months</time_frame>
    <description>Rates of recurrent exacerbation (defined as treatment with antibiotics and/or systemic corticosteroids for breathlessness, cough or wheeze), readmission to hospital, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin requirement during hospitalisation period</measure>
    <time_frame>During hospitalisation period following study entry</time_frame>
    <description>Mean daily insulin use during hospitalisation period following study entry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin A1c</measure>
    <time_frame>Follow-up (one month post study entry)</time_frame>
    <description>Mean haemoglobin A1c concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein concentration</measure>
    <time_frame>Days 7 and follow-up (one month)</time_frame>
    <description>Mean concentration of C-reactive protein in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Follow-up (one month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Follow-up (one month)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Mean forced expiratory volume in 1 second (FEV1) expressed as a percentage of predicted value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Mean serum fructosamine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of IL-6 (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of IL-8 (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of TNF-alpha (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon gamma</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of IFN-gamma (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-isoprostane</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Serum concentration of 8-isoprostane (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total carbonyl stress</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Total carbonyl stress, measured in serum (absolute value and change from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione reduced vs oxidised</measure>
    <time_frame>At hospital discharge and follow-up (one month)</time_frame>
    <description>Glutathione reduced vs oxidised, measured in serum (absolute value and change from baseline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 1 g twice daily for 28-35 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1 g twice daily for 28-35 days</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD

          -  Hospitalisation for exacerbation of COPD

          -  Age â‰¥35 years

          -  Expected to remain in hospital for at least 48 hours

        Exclusion Criteria:

          -  Prior diagnosis of diabetes mellitus requiring insulin or oral hypoglycaemic therapy

          -  Hypersensitivity to metformin hydrochloride or to any of the excipients

          -  Renal impairment

          -  Severe sepsis

          -  Metabolic acidosis

          -  Decompensated type 2 respiratory failure

          -  Severe congestive cardiac failure

          -  Acute coronary syndrome

          -  Hepatic insufficiency

          -  Excessive alcohol consumption

          -  Malnourished or at high risk for malnutrition

          -  Moribund or not for active treatment

          -  Admitted to critical care unit

          -  Unable to give informed consent

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma H Baker, MBChB PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St George's, University of London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew W Hitchings, BSc MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's Healthcare NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Tees and Hartlepool NHS Trust</name>
      <address>
        <city>Hartlepool</city>
        <state>Cleveland</state>
        <zip>TS24 9AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Morecambe Bay NHS Trust</name>
      <address>
        <city>Lancaster</city>
        <state>Cumbria</state>
        <zip>LA9 7RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Sussex Healthcare NHS Trust</name>
      <address>
        <city>Hastings</city>
        <state>East Sussex</state>
        <zip>TN37 7PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Trust</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancashire Teaching Hospitals NHS Trust</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherwood Forest Hospitals NHS Trust</name>
      <address>
        <city>Sutton-in-Ashfield</city>
        <state>Nottinghamshire</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease, COPD, metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

